Glucagon resistance in individuals with obesity and hepatic steatosis can be measured using the GLUSENTIC test and index

• DOI: 10.2337/figshare.26164945
• Publication Date: 2024-07-08T16:22:30Z
• Authors: Sasha A. S. Kjeldsen; Michael M. Richter; Nicole J. Jensen; Malin S. D. Nilsson; Niklas Heinz; Janus D. Nybing; Frederik H. Linden; Erik Høgh-Schmidt; Mikael P. Boesen; Thomas L. Andersen; Helle H. Johannesen; Samuel A. J. Tram...; Trisha J. Grevengoed; Sten Madsbad; Hendrik Vilstrup; Frank Vinholt Sch...; Andreas Møller; Elias B. Rashu; Kirsten Nørgaard; Signe Schmidt; Lise L. Gluud; Steen B. Haugaard; Jens J. Holst; Jørgen Rungby; Nicolai J. Wewer ...
• Keywords: Steatosis

<p dir="ltr">Increased plasma levels of glucagon (hyperglucagonaemia) promote diabetes development but is also observed in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This may reflect hepatic resistance towards amino acid catabolism. A clinical test for measuring has not been validated. We evaluated our sensitivity (GLUSENTIC) test, consisting two study days: a injection and measurements acids, an infusion mixed acids subsequent calculation the GLUSENTIC index (primary outcome measure) from acids. To distinguish glucagon-dependent insulin-dependent actions on metabolism, we studied type 1 (T1D). The delta-decline total was 49% lower MASLD following exogenous (p=0.01), calculated 34% (p<0.0001), T1D (p>0.99). In contrast, glucagon-induced glucose increments were similar controls (p=0.41). be used to measure individuals obesity MASLD.</p>